Christoph Brackmann - 03 Mar 2026 Form 4 Insider Report for NovoCure Ltd (NVCR)

Reporting relationship: Chief Financial Officer
Issuer ticker: NVCR
Reported as of: 03 Mar 2026
Net transaction value: -$85,314
SEC form: 4
Accepted by SEC: 05 Mar 2026, 16:31:55 UTC
Prior SEC filing: 04 Nov 2025
Source filing: View source filing
Reporting owner signature: Steven Robbins, as attorney in fact for Brackmann, Christoph

Key filing fact

Christoph Brackmann filed Form 4 for NovoCure Ltd (NVCR) on 05 Mar 2026.

Key facts

This page summarizes Christoph Brackmann's Form 4 filing for NovoCure Ltd (NVCR).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Mar 2026, 16:31.

Change

Previous filing in this sequence was filed on 04 Nov 2025.
Current net transaction value: -$85,314.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002048634 Primary reporting owner

Brackmann Christoph

Relationship: Chief Financial Officer
Address: C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE
Signature: Steven Robbins, as attorney in fact for Brackmann, Christoph
Signature date: 05 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCR transaction

Ordinary Shares

Award

Transaction value
Shares: +55,137
Change %: +41%
Price: $0.000000^*
Shares after: 189,254
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F1

NVCR transaction

Ordinary Shares

Sale

Transaction value: $85,314
Shares: -6,412
Change %: -3.4%
Price: $13.31
Shares after: 182,842
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NVCR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +80,674
Change %
Price: $0.000000^*
Shares after: 80,674
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 80,674
Exercise price: $13.30
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.

Footnote F2

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.

Footnote F4

Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.